Catalog No.
Product Name
Application
Product Information
Citations
-
GLP-1R Agonist
GLP-1R agonist 27 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), demonstrating significant oral bioactivity. It enhances cyclic adenosine monophosphate (cAMP) accumulation, which is associated with reduced blood glucose levels and decreased food intake. This compound is instrumental in research related to obesity and type 2 diabetes mellitus (T2DM), offering potential insights into therapeutic approaches for metabolic disorders. -
GLP-1R PAM
(R)-V-0219 is a positive allosteric modulator of the GLP-1 receptor (GLP-1R), functioning through enhanced receptor activation. It promotes calcium flux in human embryonic kidney (HEK) cells expressing hGLP-1R, indicating its role in metabolic regulation. This compound is particularly relevant for research focused on type 2 diabetes and obesity, allowing scientists to explore the therapeutic potentials of GLP-1R modulation. -
GLP-1R Agonist
Zabopegdutide is a selective agonist of the glucagon-like peptide 1 receptor (GLP-1R). It exhibits significant biological activity in the modulation of glucose homeostasis and appetite regulation, making it a valuable tool for obesity research. This compound can facilitate studies aimed at understanding GLP-1R signaling pathways and their implications in metabolic disorders. -
GLP-1R Agonist
GLP-1R agonist 16 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0.15 nM. This compound is known to enhance insulin secretion and promote glucose-dependent insulin release, making it a valuable tool for diabetes research. GLP-1R agonist 16 is utilized in studies focused on metabolic pathways, therapeutic development for Type 2 diabetes, and potential cardiovascular effects related to GLP-1 signaling. -
GLP-1 Receptor Agonist
GLP-1R Agonist 14 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0-20 nM for human GLP-1 receptors. This compound stimulates insulin secretion and inhibits glucagon release, making it a valuable tool for studying glucose metabolism and diabetes-related research. Its strong activity at the GLP-1R positions it as an essential reagent for investigating potential therapeutic strategies in metabolic disorders. -
GIPR Antagonist
GIPR Antagonist 1 is a potent inhibitor of the glucose-dependent insulinotropic polypeptide receptor (GIPR) with an IC50 of 4.8 nM. By effectively blocking GIPR signaling, this compound serves as a valuable tool in the study of type 2 diabetes and obesity. Its ability to modulate GIPR activity makes it significant for research focused on glucose metabolism and insulin regulation. -
GLP Receptor Agonist
GLP-1R agonist 41 is a potent agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0.0187 nM. This compound actively stimulates GLP-1 signaling pathways, playing a significant role in glucose homeostasis and insulin secretion. It is primarily used in research focused on metabolic disorders such as diabetes and obesity, as well as in the investigation of potential therapeutic interventions targeting GLP-1R. -
GLP Receptor Agonist
GLP-1R agonist 22 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 value of 0.0165 nM. This compound stimulates insulin secretion and enhances glucose homeostasis, making it a valuable tool for research in diabetes and metabolic disorders. Its specific action on GLP-1R allows for exploration of therapeutic applications in obesity and related conditions. -
GLP-1 Secretagogue
JWU-A021 is a GLP-1 secretagogue that functions by activating the TRPA1 cation channel, resulting in a calcium ion influx and increased intracellular calcium levels in enteroendocrine cells and TRPA1-transfected cells. This activation subsequently stimulates the secretion of glucagon-like peptide-1 (GLP-1) from intestinal enteroendocrine and L cells. JWU-A021 is valuable for research in the context of type 2 diabetes, offering insights into GLP-1 modulation and its potential therapeutic implications. -
GLP-1 Agonist
GLP-1R agonist 33 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R). It exhibits significant bioactivity in stimulating insulin secretion and suppressing glucagon release, making it a valuable tool for investigating metabolic disorders. This compound is particularly applicable in research focused on diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). -
GIP/GLP-1 Receptor Agonist
Acmopatide is a dual-acting agonist of the GIP and GLP-1 receptors. This compound exhibits significant biological activity in enhancing insulin secretion and regulating glucose homeostasis, making it a valuable tool in anti-diabetic research. Its unique mechanism of action supports investigations into novel therapeutic approaches for diabetes management. -
GLP-1R Agonist
GLP-1R Agonist 34 is a small molecule that functions as an agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to effective reductions in blood glucose levels. GLP-1R Agonist 34 is a valuable tool for research into metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). -
GLP-1R Agonist
GLP-1R agonist 35 selectively targets the glucagon-like peptide-1 receptor (GLP-1R) with an EC50 of 0-10 nM, demonstrating potent agonistic activity. This compound is valuable for research applications focused on diabetes and obesity, facilitating the exploration of GLP-1R modulation in metabolic disorders and potential therapeutic interventions. -
GLP-1R/GIPR Agonist
GLP-1R/GIPR agonist-2 is a selective agonist targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). It effectively enhances GIP(1-42)-induced intracellular cAMP production in human GIPR-expressing cells. This compound is valuable for research into type II diabetes mellitus, contributing to the understanding of insulin secretion and glucose homeostasis. -
GLP-1R Agonist
(Asp28)-Exenatide is a potent GLP-1 receptor agonist known for its role in glucose homeostasis. This compound is a degradation product of exenatide and retains significant biological activity, making it valuable for research applications related to diabetes and metabolism. (Asp28)-Exenatide may provide insights into the pharmacological mechanisms of GLP-1R stimulation and its effects on insulin secretion and appetite regulation. -
GLP-1 Receptor Agonist
Vensemaglutide is a GLP-1 receptor agonist that enhances insulin secretion and inhibits glucagon release in a glucose-dependent manner. This compound demonstrates significant biological activity in regulating blood glucose levels and promoting weight loss, making it useful for research in diabetes and other metabolic disorders. Its mechanism of action supports investigations into therapeutic strategies for managing conditions related to glucose homeostasis. -
GLP-1R Agonist
Taspoglutide acetate is a selective agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting a Ki value of 1.1 nM. This compound effectively stimulates cAMP accumulation in CHO-K1 cells expressing human GLP-1R, with an EC50 of 0.06 nM. In vivo studies demonstrate that Taspoglutide acetate significantly reduces blood glucose levels and elevates insulin levels in Zucker diabetic obese rats. Additionally, it has been shown to lower gastric inhibitory polypeptide (GIP) levels, plasma triglycerides, and body weight in this model, highlighting its potential for metabolic research and diabetes treatment. -
GLP-1R/GIPR Agonist
Poterepatide is a long-acting dual agonist of the GLP-1 receptor (GLP-1R) and glucose-dependent insulinotropic peptide receptor (GIPR). It demonstrates significant activity at both receptor sites, making it a valuable tool in the investigation of metabolic disorders. Poterepatide is primarily utilized in research focused on obesity and type 2 diabetes, offering insights into potential therapeutic strategies for these conditions. -
GLP-1 Receptor Agonist
Zovaglutide is a long-acting GLP-1 receptor agonist that enhances albumin binding capacity through dual fatty acid chain modification. It mediates metabolic effects via central and peripheral GLP-1 pathways, promoting satiety, reducing caloric intake, and enhancing glucose-dependent insulin secretion, without affecting GIP or glucagon receptors. This compound is well-suited for research applications related to type 2 diabetes and obesity. -
GLP-1R Agonist
Anvoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that plays a significant role in the regulation of glucose metabolism and appetite control. This compound exhibits potent antidiabetic and anti-obesity properties, making it a valuable tool for research in metabolic disorders. Its ability to enhance insulin secretion and reduce glucagon levels supports its application in studies focused on type 2 diabetes and weight management interventions. -
GLP-1R Agonist
GLP-1R modulator-1 is a potent selective agonist of the glucagon-like peptide-1 receptor (GLP-1R), acting primarily through G-protein coupled signaling pathways. This compound elevates intracellular cAMP levels, facilitating insulin secretion, delaying gastric emptying, and suppressing appetite. GLP-1R modulator-1 is valuable for research in type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). -
GLP-1 Agonist
Liraglutide acetate is an acetate derivative of Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is primarily utilized in the management of type 2 diabetes by enhancing insulin secretion, suppressing glucagon release, and promoting glucose-dependent regulation of blood sugar levels. Research applications include studies on metabolic disorders, appetite regulation, and cardiovascular effects related to GLP-1 signaling. -
GLP-1R Agonist
GLP-1R-agonist-43 is a potent GLP-1 receptor agonist with an EC50 of 2.68 nM, demonstrating significant biological activity. This compound is primarily utilized in research focused on non-insulin-dependent diabetes mellitus (type 2 diabetes) and obesity. Its capacity to stimulate the GLP-1 receptor makes it a valuable tool for investigating metabolic disorders and potential therapeutic interventions. -
GLP-1R Agonist
GLP-1R agonist 36 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting activity through receptor activation. This compound plays a crucial role in regulating glucose homeostasis and appetite control, making it a valuable tool in diabetes and obesity research. Its multiple isomers allow for comprehensive studies on receptor interaction and therapeutic potential. -
GLP Receptor Agonist
GLP-1R agonist 42 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0.0122 nM. This compound effectively stimulates insulin secretion and modulates glucagon release, making it relevant for diabetes research. Its application in metabolic studies provides insights into glucose homeostasis and potential therapeutic targets for metabolic disorders. -
GLP-1 Receptor Agonist
Berobenatide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist, which stimulates insulin secretion and inhibits glucagon release in a glucose-dependent manner. This compound plays a crucial role in enhancing glucose homeostasis and promoting weight loss. Berobenatide is primarily utilized in research related to diabetes management and obesity treatment. -
GLP-1R Agonist
GLP-1R agonist 23 is a potent agonist of the GLP-1 receptor, exhibiting an EC50 of 0.056 nM. This compound plays a critical role in enhancing insulin secretion and glucose homeostasis, making it valuable for diabetes research and therapeutic applications. Its high affinity and specificity for GLP-1R support studies aimed at understanding glucoregulatory mechanisms and developing potential treatments for metabolic disorders. -
GLP-1 Receptor Agonist
GLP-1R Agonist 13 is a selective agonist of the GLP-1 receptor, which plays a crucial role in glucose metabolism and appetite regulation. This compound exhibits potent biological activity by enhancing insulin secretion and inhibiting glucagon release, making it a valuable tool for diabetes research. Its application extends to studying metabolic disorders and evaluating potential therapeutic strategies for conditions such as type 2 diabetes and obesity. -
Glucagon Peptide
(Asp28)-Glucagon (1-29) is a modified form of the glucagon peptide, where aspartic acid (Asp) has been introduced at position 28 to enhance its aqueous solubility in physiological pH buffers. This structural optimization preserves the biological activity characteristic of glucagon. It serves as a valuable reagent for research applications that investigate glucagon's role in glucose metabolism, diabetes, and other metabolic disorders in human, rat, and porcine models. -
GLP-1 Agonist
GLP-1 Receptor Agonist 16 is a potent agonist of the GLP-1 receptor, primarily involved in regulating glucose metabolism and appetite. This compound demonstrates significant biological activity in modulating insulin secretion and promoting weight loss. It is particularly valuable in research focused on diabetes, obesity, and nonalcoholic steatohepatitis-related conditions. -
GLP-1R Agonist
GLP-1R agonist 30 is a highly selective and orally active agonist of the glucagon-like peptide-1 receptor (GLP-1R), demonstrating an EC50 of 0.048 nM. It displays significant selectivity with EC50 values greater than 20 μM for GLP-2 receptor, GIP receptor, and glucagon receptor. This compound enhances cAMP signaling while minimizing hERG inhibition, indicating favorable safety profiles. It effectively improves glucose tolerance and promotes insulin secretion in B-hGLP1R knock-in mouse models, making it a valuable tool for research applications in diabetes and metabolic disorders. -
GLP-1R/GIPR Agonist
Brenipatide is a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the gastric inhibitory polypeptide (GIP) receptor. It is primarily utilized in researching metabolic disorders, obesity, and diabetes, demonstrating significant potential in enhancing insulin secretion and promoting weight loss. This compound is essential for studies investigating the pathways and mechanisms involved in glucose homeostasis and energy balance. -
GLP-1 Receptor Agonit
Utreglutide is a potent glucagon-like peptide-1 (GLP-1) receptor agonist that plays a significant role in the regulation of glucose metabolism. This compound not only aids in lowering blood pressure and blood lipid levels but also contributes to weight reduction and enhances cardiovascular health. Utreglutide is particularly valuable in research focusing on type 2 diabetes and obesity-related conditions, facilitating a deeper understanding of metabolic disorders. -
GLP-1R Agonist
CHU-128 is a selective GLP-1 receptor (GLP-1R) agonist that effectively activates the Gs/cAMP signaling pathway. This compound is characterized by its strong signal specificity, as it does not engage the Gq/calcium signaling pathway, ERK phosphorylation, or recruit β-inhibitory proteins. CHU-128 is suitable for research applications focused on type 2 diabetes and related metabolic disorders. -
GLP-1 Receptor Positive Allosteric Modulator
GLP-1R agonist 39 is a potent positive allosteric modulator of the GLP-1 receptor. This compound enhances the activity of the GLP-1 receptor, making it valuable for studies related to obesity and type 2 diabetes. Its application in research enables the exploration of therapeutic strategies aimed at metabolic disorders. -
GLP-1R Agonist
GLP-1R agonist 38 is a selective agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound exhibits significant biological activity in enhancing insulin secretion, suppressing glucagon release, and promoting weight reduction, making it a valuable tool for studying metabolic disorders. It is applicable in research related to type II diabetes mellitus (T2DM), obesity, and non-alcoholic fatty liver disease (NASH). -
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist 18 is a potent GLP-1 receptor agonist with an EC50 of 0.22 nM. This compound demonstrates significant biological activity by lowering blood glucose levels and promoting weight loss, making it valuable for diabetes research. Its efficacy in modulating GLP-1 receptor signaling positions it as a useful tool for investigating therapeutic strategies in metabolic disorders. -
GLP-1R Agonist
GLP-1R agonist 26 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of less than 10 nM. This compound plays a crucial role in enhancing insulin secretion, promoting weight loss, and exhibiting cardioprotective effects. It is primarily utilized in research focused on metabolic disorders, diabetes, and obesity treatment. -
GLP-1R Agonist
GLP-1R agonist 29 is a potent agonist of the GLP-1 receptor, effectively stimulating cAMP production with an EC50 value of 0.018 nM. This compound demonstrates favorable pharmacokinetic properties, evidenced by a robust body exposure reflected in an AUC0-∞,sc of 77688 ng·h/mL. It serves as a valuable tool for research applications related to metabolic disorders and diabetes, allowing for exploration of GLP-1R signaling pathways. -
GLP-1R Agonist
GLP-1R Agonist 25 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 value of 0.167 nM. This compound plays a crucial role in stimulating insulin secretion and regulating glucose metabolism, making it a valuable tool for research focused on type II diabetes and related metabolic disorders. Its potent biological activity supports the exploration of therapeutic strategies aimed at improving glycemic control. -
GPR120 Agonist
AZ13581837 is a potent GPR120 agonist, demonstrating human and mouse EC50 values of 5.2 nM and 4.3 nM, respectively. This compound activates Gαq, Gαs, and β-arrestin signaling pathways, effectively reducing cAMP levels, stimulating GLP-1 secretion, promoting glucose lowering, and enhancing insulin secretion. AZ13581837 is valuable for research related to type 2 diabetes, providing insights into potential therapeutic strategies targeting metabolic disorders. -
GPR119 Agonist
AS1269574 is a potent agonist of GPR119, exhibiting an EC50 of 2.5 μM in HEK293 cells expressing the human receptor. This compound activates TRPA1 cation channels, thereby facilitating the secretion of glucagon-like peptide-1 (GLP-1). Notably, AS1269574 induces glucose-dependent insulin secretion from pancreatic β-cells exclusively under high-glucose conditions, making it a valuable tool for research into type 2 diabetes. -
GPR119 Agonist
K-833 is a potent GPR119 agonist with EC50 values of 39.8 nM in humans, 100 nM in mice, 75.4 nM in rats, and 12.6 nM in dogs. This compound enhances GLP-1 secretion and exhibits a synergistic effect on GLP-1 levels when administered alongside AM-5262 in acute gut peptide secretion assays in mice. K-833 is suitable for research focusing on weight loss and metabolic regulation. -
Active Metabolite of Cannabinol
11-Hydroxy cannabinol is an active metabolite of Cannabinol, primarily targeting cannabinoid receptors in the endocannabinoid system. This compound exhibits biological activity that may influence numerous physiological processes, including pain modulation and anti-inflammatory effects. It is utilized in preclinical research to explore therapeutic applications related to cannabinoid signaling pathways and their potential impact on various health conditions. -
Xylazine Metabolite
2,6-Dimethylphenylthiourea is a metabolite of xylazine, an established α2-adrenergic agonist. This compound serves as a valuable tool in pharmacological research, specifically in studies examining the metabolic pathways of xylazine and its effects on α2-adrenergic receptors. It provides insights into its pharmacokinetics and potential physiological implications. -
Adenosine A2A Receptor Inhibitor
4-Desmethyl Istradefylline is a selective adenosine A2A receptor antagonist, serving as a significant metabolite of Istradefylline. With a Ki of 2.2 nM, it demonstrates potent inhibition of the A2A receptor, making it relevant for exploring therapeutic strategies in Parkinson's disease and related neurological disorders. Its oral bioactivity allows for convenience in in vivo research applications targeting adenosine signaling pathways. -
Stable Isotope
Quetiapine Sulfoxide-d8 is a deuterated analog of Quetiapine sulfoxide, a primary metabolite of the second-generation antipsychotic Quetiapine. This compound acts as a 5-HT receptor agonist and dopamine receptor antagonist, playing a critical role in the pharmacokinetic studies of Quetiapine metabolism. Quetiapine Sulfoxide-d8 is commonly utilized in research applications involving drug metabolism, pharmacology, and analytical chemistry, particularly in the development and validation of quantitation methods in biological samples. -
Pergolide Metabolite
Pergolide sulfone is a metabolite of Pergolide, primarily acting as a dopamine receptor agonist. This compound exhibits significant dopaminergic activity, making it relevant for research into Parkinson's disease and other neurological disorders. Pergolide sulfone can be utilized in studies investigating the pharmacological profiles of dopamine receptor interactions and their implications in neurodegenerative conditions. -
Drug Derivative
(±)-p-Fluoro pseudoephedrine hydrochloride is a drug derivative associated with the pharmacological activity of pseudoephedrine. This compound exhibits decongestant properties, primarily functioning as a sympathomimetic agent that influences adrenergic receptors. Its biological activity is employed in studies related to respiratory distress, providing valuable insights into drug metabolism and therapeutic efficacy in treatments for nasal congestion. -
MMB-CHMICA Metabolite
MMB-ICA is a metabolite of MMB-CHMICA, primarily targeting the cannabinoid receptor system. This compound demonstrates significant biological activity in modulating receptor signaling pathways, making it valuable for research in cannabinoid pharmacology. MMB-ICA is utilized in studies investigating the therapeutic potential of cannabinoids and their metabolic pathways.
